Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) 30% HIGHER; will continue to develop CPP-109 (Catalyst’s version of vigabatrin) for the treatment of cocaine and methamphetamine addiction. The Company’s decision was made after, and based upon, an in-depth review of the results obtained from its 186-patient Phase II clinical trial evaluating the use of CPP-109 for the treatment of cocaine addiction (CPP-01004) and the top-line results obtained from its 57-patient proof-of-concept study evaluating the use of CPP-109 for the treatment of methamphetamine addiction (CPP-02001).

Penske Automotive Group, Inc. (NYSE: PAG) 10% LOWER; erminated its discussions with General Motors Company to